DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dr. Reddy's announces the first-to-market launch of over-the-counter, store-brand equivalent of Allegra-D(r) 24 HR in the U.S. Market DR.REDDY'S LABORATORIES LTD. - 500124 - Earnings Call Notification For Q1 FY23
Earnings call notification for Q1 FY23 DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper advertisement for notice of AGM and evoting instructions
Dr Reddy's gains over 3% on new drug launch in the US market
The company launched its generic version of fesoterodine fumarate extended-release tablets that can be used for treating overactive bladder in the US market. Dr Reddy's launches Fesoterodine Fumarate tablets in US
The tablets are available in doses of 4 mg and 8 mg DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dr. Reddy''s Laboratories announces the launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. market
Andhra plant gets two observations from USFDA: Dr Reddy's Laboratories
The inspection was conducted from June 30, 2022 to July 7, 2022. 
Dr Reddy's says it aims to triple reach to 1.5 bn patients by 2030
Under its sustainability goals for the next decade, Dr Reddy's said it is making its "products accessible and affordable for patients" and "25 per cent of new launches to be first to market by 2027" 